1. Bansal, S.,P. E. Pergola, Current Management of Hyperkalemia in Patients on Dialysis.【J】 Kidney Int Rep, 2020. 5: p. 779-789.
2. Giebisch, G., Renal potassium transport: mechanisms and regulation.【J】 Am J Physiol, 1998. 274: p. F817-33.
3. Zhang, Luxia, Fang Wang, Li Wang, et al., Prevalence of chronic kidney disease in China: a cross-sectional survey.【J】 The Lancet, 2012. 379: p. 815-822.
4. Sun, L., L. X. Zou, Y. C. Han, et al., Forecast of the incidence, prevalence and burden of end-stage renal disease in Nanjing, China to the Year 2025.【J】 BMC Nephrol, 2016. 17: p. 60-68.
5. 全国血液净化病例信息登记系统, in CNRDS. 2021.
6. Karaboyas, A., B. M. Robinson, G. James, et al., Hyperkalemia excursions are associated with an increased risk of mortality and hospitalizations in hemodialysis patients.【J】 Clin Kidney J, 2021. 14: p. 1760-1769.
7. 赵新菊, 牛庆雨, 甘良英, et al., 基于DOPPS研究分析中国血液透析患者高钾血症的患病率及相关影响因素 【J】 中国血液净化, 2021. 20: p. 145-150,156.
8. 毛慧娟, 黄耀禹 邢昌赢, 维持性血液透析患者高钾血症及其反复发作的相关因素.【J】 中华医学杂志, 2021. 101: p. 3484-3489.
9. Rossignol, P., Z. Lamiral, L. Frimat, et al., Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey.【J】 Nephrol Dial Transplant, 2017. 32: p. 2112-2118.
10. Zehnder, C., J. P. Gutzwiller, A. Huber, et al., Low-potassium and glucose-free dialysis maintains urea but enhances potassium removal.【J】 Nephrol Dial Transplant, 2001. 16: p. 78-84.
11. A. Blumberg, H. W. Roser, C. Zehnder and J. Mu¨ller-Brand, Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium.【J】 Nephrol Dial Transplant, 1997. 12: p. 1629–1634.
12. Pun, P. H., R. W. Lehrich, E. F. Honeycutt, et al., Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics.【J】 Kidney Int, 2011. 79: p. 218-27.
13. Bem, D., D. Sugrue, B. Wilding, et al., The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review.【J】 Ren Fail, 2021. 43: p. 241-254.
14. Cheung AK, Chang TI, Cushman WC, Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.【J】 Kidney Int, 2021. 99: p. 559-569.
15. Ben Salem, C., A. Badreddine, N. Fathallah, et al., Drug-induced hyperkalemia.【J】 Drug Saf, 2014. 37: p. 677-92.
16. Bird, S. T., S. R. Pepe, M. Etminan, et al., The association between drospirenone and hyperkalemia: a comparative-safety study.【J】 BMC Clin Pharmacol, 2011. 11: p. 23.
17. 梅长林 陈晓农, 郝传明, 慢性肾脏病高钾血症风险评估模型的建立[J].中华医学杂志.【J】 中华医学杂志, 2020. 100: p. 3498-3503.
18. 邢晓阳, 姚兰, 王沛, 血液透析患者发生高钾血症的危险因素分析及风险预测模型的建立与验证.【J】 中华医学杂志, 2021. 101: p. 3495-3500.
19. 韩旭, 边佳明 左力 赵厚宇, 中国门诊患者高钾血症分布及诊疗现状的流行病学研究.【J】 中国血液净化, 2020. 19: p. 726-746.
20. Burnell, J. M., B. H. Scribner, B. T. Uyeno, et al., The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium.【J】 J Clin Invest, 1956. 35: p. 935-9.
21. Kim, H. J., Pathogenesis and treatment of dyskalemia in maintenance hemodialysis and CAPD.【J】 Electrolyte Blood Press, 2006. 4: p. 47-52.
22. Karaboyas, A., J. Zee, S. M. Brunelli, et al., Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS).【J】 Am J Kidney Dis, 2017. 69: p. 266-277.
23. Clase, C. M., J. J. Carrero, D. H. Ellison, et al., Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.【J】 Kidney Int, 2020. 97: p. 42-61.
24. Bianchi, S., F. Aucella, L. De Nicola, et al., Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology.【J】 J Nephrol, 2019. 32: p. 499-516.
25. Foundation, National Kidney, K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease 【J】 2004.
26. 梅长林, 中国围透析期慢性肾脏病管理规范.【J】 中华肾脏病杂志, 2021. 37: p. 690-704.
27. 赵光远,王荃, 高钾血症和低钾血症危象.【J】 中国小儿急救医学, 2020. 27: p. 572-576.
28. NKF, Clinical update on hyperkalemia, in National Kidney foundation
29. 陈江华, 中国慢性肾脏病患者血钾管理实践专家共识.【J】 中华肾脏病杂志, 2020. 36: p. 781-792.
30. Goyal, A., J. A. Spertus, K. Gosch, et al., Serum potassium levels and mortality in acute myocardial infarction.【J】 Jama, 2012. 307: p. 157-64.
31. Lindner, G., E. A. Burdmann, C. M. Clase, et al., Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference.【J】 Eur J Emerg Med, 2020. 27: p. 329-337.
32. Durfey, N., B. Lehnhof, A. Bergeson, et al., Severe Hyperkalemia: Can the Electrocardiogram Risk Stratify for Short-term Adverse Events?【J】 West J Emerg Med, 2017. 18: p. 963-971.
33. Nemati, E.,S. Taheri, Electrocardiographic manifestations of hyperkalemia in hemodialysis patients.【J】 Saudi J Kidney Dis Transpl, 2010. 21: p. 471-7.
34. Montague, B. T., J. R. Ouellette,G. K. Buller, Retrospective review of the frequency of ECG changes in hyperkalemia.【J】 Clin J Am Soc Nephrol, 2008. 3: p. 324-30.
35. Varga, Csaba, Zsolt Kálmán, Alíz Szakáll, et al., ECG alterations suggestive of hyperkalemia in normokalemic versus hyperkalemic patients.【J】 BMC Emergency Medicine, 2019. 19.
36. Hollander-Rodriguez, J. C.,J. F. Calvert, Jr., Hyperkalemia.【J】 Am Fam Physician, 2006. 73: p. 283-90.
37. 国家肾脏病医疗质量控制中心, 血液净化标准操作规程. 2021.
38. Nilsson, E., A. Gasparini, J. Arnlov, et al., Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system.【J】 Int J Cardiol, 2017. 245: p. 277-284.
39. Yusuf, A. A., Y. Hu, B. Singh, et al., Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study.【J】 Am J Nephrol, 2016. 44: p. 179-86.
40. Agar, B. U., B. F. Culleton, R. Fluck, et al., Potassium kinetics during hemodialysis.【J】 Hemodial Int, 2015. 19: p. 23-32.
41. Ohnishi, T., M. Kimachi, S. Fukuma, et al., Postdialysis Hypokalemia and All-Cause Mortality in Patients Undergoing Maintenance Hemodialysis.【J】 Clin J Am Soc Nephrol, 2019. 14: p. 873-881.
42. Cooper, L. B., G. Savarese, J. J. Carrero, et al., Clinical and research implications of serum versus plasma potassium measurements.【J】 Eur J Heart Fail, 2019. 21: p. 536-537.
43. Hartland, A. J.,R. H. Neary, Serum potassium is unreliable as an estimate of in vivo plasma potassium.【J】 Clin Chem, 1999. 45: p. 1091-2.
44. Truhlá?, A., C. D. Deakin, J. Soar, et al., European Resuscitation Council Guidelines for Resuscitation 2015: Section 4. Cardiac arrest in special circumstances.【J】 Resuscitation, 2015. 95: p. 148-201.
45. Freeman, K., J. A. Feldman, P. Mitchell, et al., Effects of presentation and electrocardiogram on time to treatment of hyperkalemia.【J】 Acad Emerg Med, 2008. 15: p. 239-49.
46. Ryuge, A., A. Nomura, H. Shimizu, et al., Warning: The ECG May Be Normal in Severe Hyperkalemia.【J】 Intern Med, 2017. 56: p. 2243-2244.
47. Kovesdy, Csaba P., Deborah L. Regidor, Rajnish Mehrotra, et al., Serum and Dialysate Potassium Concentrations and Survival in Hemodialysis Patients.【J】 Clinical Journal of the American Society of Nephrology, 2007. 2: p. 999-1007.
48. Brunelli, S. M., C. Du Mond, N. Oestreicher, et al., Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval.【J】 Am J Kidney Dis, 2017. 70: p. 21-29.
49. Maclaughlin, H. L., D Kariyawasam, S. Kenny, et al. Pro-active individualised dietary modification reduces the prevalence of hyperkalaemia in patients with advanced CKD. 2015 [cited www.britishrenal.org/ukkw2018-2/2015-abstracts.
50. St-Jules, D. E., D. S. Goldfarb,M. A. Sevick, Nutrient Non-equivalence: Does Restricting High-Potassium Plant Foods Help to Prevent Hyperkalemia in Hemodialysis Patients?【J】 J Ren Nutr, 2016. 26: p. 282-7.
51. Bernier-Jean, Amelie, Germaine Wong, Valeria Saglimbene, et al., Dietary Potassium Intake and All-Cause Mortality in Adults Treated with Hemodialysis.【J】 Clinical Journal of the American Society of Nephrology, 2021. 16: p. 1851-1861.
52. Khoueiry, G., A. Waked, M. Goldman, et al., Dietary intake in hemodialysis patients does not reflect a heart healthy diet.【J】 J Ren Nutr, 2011. 21: p. 438-47.
53. Kalantar-Zadeh, K.,D. Fouque, Nutritional Management of Chronic Kidney Disease.【J】 N Engl J Med, 2017. 377: p. 1765-1776.
54. Saglimbene, V. M., G. Wong, M. Ruospo, et al., Fruit and Vegetable Intake and Mortality in Adults undergoing Maintenance Hemodialysis.【J】 Clin J Am Soc Nephrol, 2019. 14: p. 250-260.
55. Kalantar-Zadeh, K., A. R. Tortorici, J. L. Chen, et al., Dietary restrictions in dialysis patients: is there anything left to eat?【J】 Semin Dial, 2015. 28: p. 159-68.
56. 王饶萍, 叶晓青, 唐春苑, et al., 个体及互动式集体健康教育对维持性血液透析患者高钾血症的影响.【J】 现代临床护理, 2016: p. 64-67.
57. Burrowes, J. D.,N. J. Ramer, Removal of potassium from tuberous root vegetables by leaching.【J】 J Ren Nutr, 2006. 16: p. 304-11.
58. 中华人民共和国国家卫生和计划生育委员会, 慢性肾脏病患者膳食指导. 2017.
59. Alfonzo, Dr Annette, Clinical Practice Guidelines Treatment of Acute Hyperkalaemia in Adults.【J】 2020.
60. Wheeler, D. T., S. J. Schafers, T. A. Horwedel, et al., Weight-based insulin dosing for acute hyperkalemia results in less hypoglycemia.【J】 J Hosp Med, 2016. 11: p. 355-7.
61. Sterns, R. H., M. Grieff,P. L. Bernstein, Treatment of hyperkalemia: something old, something new.【J】 Kidney Int, 2016. 89: p. 546-54.
62. Rossignol, P., M. Legrand, M. Kosiborod, et al., Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future.【J】 Pharmacol Res, 2016. 113: p. 585-591.
63. Long, B., J. R. Warix,A. Koyfman, Controversies in Management of Hyperkalemia.【J】 J Emerg Med, 2018. 55: p. 192-205.
64. Stavros, F., A. Yang, A. Leon, et al., Characterization of structure and function of ZS-9, a K+ selective ion trap.【J】 PLoS One, 2014. 9: p. e114686.
65. Kosiborod, Mikhail, Henrik S. Rasmussen, Philip Lavin, et al., Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia.【J】 Jama, 2014. 312.
66. 曾小庆, 龚杰 柳园, 维持性血液透析患者透析充分性的影响因素分析.【J】 现代预防医学, 2020. 47: p. 1138-1141.
67. Kovesdy, C. P., K. Matsushita, Y. Sang, et al., Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.【J】 Eur Heart J, 2018. 39: p. 1535-1542.
68. Dolson, G. M., K. J. Ellis, M. V. Bernardo, et al., Acute decreases in serum potassium augment blood pressure.【J】 Am J Kidney Dis, 1995. 26: p. 321-6.
69. Buemi, M., E. Aloisi, G. Coppolino, et al., The effect of two different protocols of potassium haemodiafiltration on QT dispersion.【J】 Nephrol Dial Transplant, 2005. 20: p. 1148-54.
70. Morrison, G., E. L. Michelson, S. Brown, et al., Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients.【J】 Kidney Int, 1980. 17: p. 811-9.
71. 罗世露, 刘研 段彤月, 不同钾离子浓度透析液在透析患者高钾血症中的应用新进展.【J】 中华医学杂志, 2021. 101: p. 3517-3520.
72. Sandle, G. I., E. Gaiger, S. Tapster, et al., Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis.【J】 Clin Sci (Lond), 1987. 73: p. 247-52.
73. Fishbane, S., M. Ford, M. Fukagawa, et al., A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.【J】 J Am Soc Nephrol, 2019. 30: p. 1723-1733.
74. 康冬, 白婵 尚进, 环硅酸锆钠散对慢性肾脏病高钾血症患者短期降钾效果的临床观察.【J】 中华医学杂志, 2020. 100: p. 2997-3000.
75. Zhang, Y., R. Xu, F. Wang, et al., Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.【J】 Cardiovasc Drugs Ther, 2021. 35: p. 1057-1066.
76. Morales, E., P. Cravedi,J. Manrique, Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options.【J】 Front Med (Lausanne), 2021. 8: p. 653634.
77. Wang, J., M. M. Lv, O. Zach, et al., Calcium-Polystyrene Sulfonate Decreases Inter-Dialytic Hyperkalemia in Patients Undergoing Maintenance Hemodialysis: A Prospective, Randomized, Crossover Study.【J】 Ther Apher Dial, 2018. 22: p. 609-616.
78. Nakayama, Y., K. Ueda, S. I. Yamagishi, et al., Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia.【J】 Clin Exp Nephrol, 2018. 22: p. 35-44.
79. Spinowitz, B. S., S. Fishbane, P. E. Pergola, et al., Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.【J】 Clin J Am Soc Nephrol, 2019. 14: p. 798-809.
80. Palmer, B. F., Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.【J】 Mayo Clin Proc, 2020. 95: p. 339-354.
81. Yu, M. Y., J. H. Yeo, J. S. Park, et al., Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients.【J】 PLoS One, 2017. 12: p. e0173542.
82. Bieber, B., J. Qian, S. Anand, et al., Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and Quality of Life in the China Dialysis Outcomes and Practice Patterns study.【J】 Nephrol Dial Transplant, 2014. 29: p. 1770-7.
83. Zandi-Nejad, DBMK:Disorders of potassium balance.【J】 Brenner and Rector’s the Kidne, 2011: p. 640-6885.
84. Ponikowski P , V oors AA, Anker SD, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the T ask Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.【J】 Eur Heart J, 2016. 37: p. 2129-2200.
85. Liu, Y., X. Ma, J. Zheng, et al., Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.【J】 BMC Nephrol, 2017. 18: p. 206.
86. Maddirala, S., A. Khan, A. Vincent, et al., Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.【J】 Am J Med Sci, 2008. 336: p. 330-5.
87. Desai, A. S., K. Swedberg, J. J. McMurray, et al., Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.【J】 J Am Coll Cardiol, 2007. 50: p. 1959-66.
88. Yildirim, T., M. Arici, S. Piskinpasa, et al., Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?【J】 Ren Fail, 2012. 34: p. 1095-9.
89. Qiao, Y., J. I. Shin, T. K. Chen, et al., Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.【J】 JAMA Intern Med, 2020. 180: p. 718-726.
90. Efrati, S., R. Zaidenstein, V. Dishy, et al., ACE inhibitors and survival of hemodialysis patients.【J】 Am J Kidney Dis, 2002. 40: p. 1023-9.
91. Suzuki, H., Y. Kanno, S. Sugahara, et al., Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.【J】 Am J Kidney Dis, 2008. 52: p. 501-6.
92. Writing, Committee, T. M. Maddox, J. L. Januzzi, Jr., et al., 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.【J】 J Am Coll Cardiol, 2021. 77: p. 772-810.
93. 许顶立, 张健 张宇辉, 中国心力衰竭患者离子管理专家共识.【J】 中华心力衰竭和心肌病杂志 2020. 4: p. 16-31.
94. Matsumoto, Y., Y. Mori, S. Kageyama, et al., Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.【J】 J Am Coll Cardiol, 2014. 63: p. 528-36.
95. Lin, C., Q. Zhang, H. Zhang, et al., Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.【J】 J Clin Hypertens (Greenwich), 2016. 18: p. 121-8.
96. Quach, K., L. Lvtvyn, C. Baigent, et al., The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.【J】 Am J Kidney Dis, 2016. 68: p. 591-598.
97. Walsh, M., B. Manns, A. X. Garg, et al., The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.【J】 Clin J Am Soc Nephrol, 2015. 10: p. 1602-8.
98. Charytan, D. M., J. Himmelfarb, T. A. Ikizler, et al., Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.【J】 Kidney Int, 2019. 95: p. 973-982.
99. Hammer, F., U. Malzahn, J. Donhauser, et al., A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.【J】 Kidney Int, 2019. 95: p. 983-991.
100. 倪彤, 潘静, 常用中药和方剂中钾含量的聚类分析及临床应用.【J】 中西医结合心血管病电子杂志, 2018. 34: p. 33-35.
101. 王宇晖, 楼正青, 陈筱凡, 常用中药水煎剂含钾量分析.【J】 中国中西医结合肾病杂志, 2004. 09: p. 531-531.
